Theriva Biologics, Inc.
Theriva Biologics, Inc. (TOVX): 3 pipeline candidates · ~19 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.5 months
0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Theriva Biologics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.6M
Cash
$14.5M
Quarterly Burn
$2.5M
Runway
18.5 mo
Revenue
$300K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$307K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 450,263 | $88K |
| vanguard capital management llc | 384,808 | $75K |
| vanguard fiduciary trust co | 241,780 | $47K |
| jane street group, llc | 177,034 | $35K |
| two sigma securities, llc | 105,241 | $21K |
| xtx topco ltd | 94,620 | $19K |
| boothbay fund management, llc | 27,646 | $5K |
| morgan stanley | 23,602 | $5K |
| stonex group inc. | 22,280 | $4K |
| two sigma investments, lp | 15,441 | $3K |
Showing top 10 of 19 institutional holders of Theriva Biologics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Theriva Biologics, Inc.'s pipeline?
Theriva Biologics, Inc. (TOVX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Theriva Biologics, Inc.'s lead drug candidate?
Theriva Biologics, Inc.'s most advanced tracked candidate is syn-004 (Phase 1/Phase 2) for Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant.
What is Theriva Biologics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Theriva Biologics, Inc. has approximately 18.5 months of cash runway.
What is Theriva Biologics, Inc.'s market capitalization?
Theriva Biologics, Inc.'s market capitalization is approximately $12.6M.
Who is the CEO of Theriva Biologics, Inc.?
Mr. Steven A. Shallcross CPA is the chief executive officer of Theriva Biologics, Inc. (TOVX).
Get the full picture on Theriva Biologics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.